Cisplatin-based chemotherapy is the treatment of choice in mUC. A significant proportion of patients do not receive chemotherapy, while about 50% of treated patients do not receive cisplatin. We used the multinational RISC database to map patterns of chemotherapy utilization and adherence to recently published UFC criteria (Galsky, 2011) in unselected mUC patients
Selection criteria: diagnosis of mUC, transitional-cell, mixed, squamous and adeno histologies.
Of 1974 mUC patients 475 (25%) did not receive 1st-line chemotherapy. No chemotherapy administration was associated with: non-pure TCC histology, higher Charslon Comorbidity Index (CCI), non-caucasian race, non-european country, low volume center (contribution of
Patterns of practice are influenced by various factors, such as age, co-morbidities, race, country of origin and volume of mUC patients. 25% of non-cisplatin treated patients were fit-for-cisplatin. Age and co-morbidities represent major factors, which lead to deviation from the established UFC criteria.
Clinical trial identification
Legal entity responsible for the study
Icahn School of Medicine, Mount Sinai USA
All authors have declared no conflicts of interest.